S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The 3-Stock Retirement Blueprint (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The 3-Stock Retirement Blueprint (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The 3-Stock Retirement Blueprint (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The 3-Stock Retirement Blueprint (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:HRTX

Heron Therapeutics - HRTX Stock Forecast, Price & News

$2.76
+0.08 (+2.99%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.54
$2.77
50-Day Range
$2.60
$4.67
52-Week Range
$2.19
$10.46
Volume
2.25 million shs
Average Volume
2.30 million shs
Market Capitalization
$328.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

Heron Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
247.8% Upside
$9.60 Price Target
Short Interest
Bearish
23.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($0.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

641st out of 1,034 stocks

Pharmaceutical Preparations Industry

310th out of 502 stocks

HRTX stock logo

About Heron Therapeutics (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

Heron Therapeutics Is Not Out Of The Woods Yet
Heron Awaits FDA Decision On HTX-019
3 Stocks Expecting Good News From the FDA
Heron Shares Jump After Equity Financing, Q2 Earnings
Earnings Outlook For Heron Therapeutics
Heron Therapeutics To Axe 34% Jobs
See More Headlines
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Company Calendar

Last Earnings
11/03/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
302
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.60
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+247.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-220,680,000.00
Net Margins
-220.55%
Pretax Margin
-220.55%

Debt

Sales & Book Value

Annual Sales
$86.35 million
Book Value
$0.19 per share

Miscellaneous

Free Float
112,920,000
Market Cap
$328.14 million
Optionable
Optionable
Beta
0.88

Key Executives

  • Dr. Barry D. Quart Pharm.D. (Age 65)
    Chairman & CEO
    Comp: $1.1M
  • Mr. John W. Poyhonen (Age 62)
    Pres & Chief Commercial Officer
    Comp: $722.35k
  • Mr. David L. Szekeres (Age 48)
    Exec. VP & COO
    Comp: $710.66k
  • Ms. Lisa Peraza (Age 45)
    VP & Chief Accounting Officer
    Comp: $474.1k
  • Ms. Kimberly J. ManhardMs. Kimberly J. Manhard (Age 62)
    Exec. VP of Drug Devel. & Director
    Comp: $739.8k
  • Mr. Sean T. Ristine (Age 52)
    Sr. VP of HR
  • Dr. Thomas B. Ottoboni Ph.D. (Age 63)
    Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences
  • Mr. Michael E. Mathews (Age 59)
    Sr. VP of Acute Care
  • Dr. Chris M. Storgard (Age 56)
    Chief Medical Officer













HRTX Stock - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 1-year price targets for Heron Therapeutics' shares. Their HRTX share price forecasts range from $5.50 to $15.00. On average, they expect the company's stock price to reach $9.60 in the next year. This suggests a possible upside of 247.8% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2022?

Heron Therapeutics' stock was trading at $9.13 on January 1st, 2022. Since then, HRTX stock has decreased by 69.8% and is now trading at $2.76.
View the best growth stocks for 2022 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.09. The biotechnology company had revenue of $23.23 million for the quarter, compared to the consensus estimate of $25.04 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 848.19% and a negative net margin of 220.55%. During the same quarter in the prior year, the company posted ($0.64) EPS.

What guidance has Heron Therapeutics issued on next quarter's earnings?

Heron Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $107.14 million.

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.79%), State Street Corp (7.43%), Vanguard Group Inc. (7.36%), Tang Capital Management LLC (5.75%), Palisade Capital Management LLC NJ (2.85%) and Rubric Capital Management LP (2.12%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $2.76.

How much money does Heron Therapeutics make?

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $328.14 million and generates $86.35 million in revenue each year. The biotechnology company earns $-220,680,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Heron Therapeutics have?

The company employs 302 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.

This page (NASDAQ:HRTX) was last updated on 12/4/2022 by MarketBeat.com Staff